Simplify Logo

Full-Time

Senior Director

FP&a Financial Systems and Operations

Confirmed live in the last 24 hours

Voyager Therapeutics

Voyager Therapeutics

51-200 employees

Develops genetic medicines for neurological diseases

Hardware
Biotechnology
Healthcare

Senior, Expert

Lexington, MA, USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Communications
Management
Data Analysis
Requirements
  • A minimum of a Bachelor’s degree in Finance or Accounting is required.
  • Experience in biotech/life sciences required.
  • Demonstrated success in driving FP&A engagement and activities in prior organizations. Individual also needs to have demonstrated their ability to develop, implement, and drive system and process improvements.
  • Strong independent and team-oriented contributor with great communication skills.
  • Experience working in a fast-paced, growing (early-stage) environment is ideal.
  • Ability to provide the highest standards of accuracy and precision; highly organized and attention to detail required.
  • Individual needs to be strategic, while being very tactical and hands on in getting the work completed.
  • Articulate with excellent verbal and written communication skills.
  • Ability to think creatively, highly driven and self-motivated.
  • Demonstrated ability to roll-up sleeves and work in a collaborative, scalable fashion.
  • Advanced experience with Microsoft Office Suite, to include advanced Excel and Power Point skills.
  • Experience with Adaptive Insights or similar planning software (i.e., Hyperion, Essbase, etc.) is required.
Responsibilities
  • Lead Voyager’s planning and forecasting processes to enable execution of the company’s strategic priorities including:
  • Long Range Operating Planning Process, driving organizational focus and establishment of long-term planning.
  • Annual Operating Planning Process, developing rigorous budgeting and forecasting processes to support Voyager’s growth and change.
  • Drive preparation and delivery of financial management reporting to all stakeholders with clear communication around business drivers and future implications.
  • Develop key dashboards and management tools to assist management in the strategic and tactical management of the company.
  • Create and monitor key performance indicators (KPIs), highlighting trends and analyzing causes of unexpected variance.
  • Partner and collaborate across multiple cross-functional departments, including Executive Leadership to provide financial support/guidance necessary to drive alignment and sound decision making.
  • Ensure that financial considerations/impacts are appropriately incorporated into project team discussions and any project governance interactions.
  • Develop a more integrated financial valuation and project management process which incorporates all the necessary components that are required to assess internal program valuations while integrating external opportunities.
  • Drive analytics and modeling for potential business development activities, including valuations and scenario planning.
  • Provide support for on-going external alliances and collaborations. Ensure that financial commitments are understood and met by Voyager and the partner.
  • Analyze financial information and reports to provide timely financial recommendations to management for decision making purposes.
  • Partner with the Accounting team on monthly, quarterly, and annual closing and reporting processes.
  • Utilize existing systems and tools and/or acquire new tools to automate and streamline all things FP&A with a focus on budgeting, forecasting, valuations, etc.
  • Own and lead all things related to continuous system and process improvement within the finance organization to streamline processes and improve communication and flow of information to the business, reduce daily workload and enhance financial reporting and communication across the company.
  • Prepare and lead discussions around financial reporting and information at key meeting including Monthly Business Reviews, SLT Meetings, Board Meetings, Audit Committee Meetings, etc.
  • Seek opportunities to raise the financial acumen across the organization.

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) technology to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed for neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from severe neurological disorders.

Company Stage

IPO

Total Funding

$344M

Headquarters

Cambridge, Massachusetts

Founded

2014

Growth & Insights
Headcount

6 month growth

7%

1 year growth

28%

2 year growth

47%
Simplify Jobs

Simplify's Take

What believers are saying

  • Voyager's recent $100 million upfront payment from Novartis highlights strong financial backing and potential for rapid growth.
  • The appointment of experienced executives like Nathan Jorgensen as CFO and Toby Ferguson as CMO strengthens the company's leadership team.
  • The selection of a development candidate for the GBA1 program in collaboration with Neurocrine Biosciences demonstrates the productivity and potential of their partnerships.

What critics are saying

  • The highly specialized focus on neurological diseases may limit market opportunities compared to broader biotech firms.
  • Dependence on partnerships and milestone payments introduces financial uncertainty if collaborations do not yield expected results.

What makes Voyager Therapeutics unique

  • Voyager Therapeutics leverages its proprietary AAV capsid discovery platform to deliver genetic material directly to the brain, a significant advancement over traditional methods.
  • The company's focus on crossing the blood-brain barrier addresses a critical challenge in treating neurological diseases, setting it apart from many competitors.
  • Voyager's strong emphasis on collaborative partnerships with major pharmaceutical companies like Novartis accelerates its R&D and commercialization efforts.